Adult polymyalgia rheumatica; evidence, access and incremental franchise economicsNovember 18, 2026

Cosentyx Adds a PMR Market for Novartis: Steroid-Sparing Evidence Must Translate into Treatment Persistence

NVS

Executive Summary

The US PMR indication gives Novartis a defined expansion opportunity supported by randomized remission evidence. Commercial value depends on eligible patients, safe steroid tapering, access and persistence in a market with an existing biologic option. BioScore unverified; no editorial investment rating assigned.

For people with polymyalgia rheumatica, controlling shoulder and hip pain is only part of the treatment problem. Repeated relapse during steroid reduction can prolong exposure to a treatment that has its own cumulative burdens. A biologic that helps maintain remission while steroids are tapered can therefore offer meaningful value beyond an improvement in an inflammatory laboratory result.

Cosentyx, or secukinumab, now has a US indication for adults with PMR whose response to corticosteroids is inadequate or who cannot tolerate tapering. The US Novartis announcement is dated November 16; the global announcement is dated November 17. The underlying REPLENISH results were published online on June 3, 2026. The current development is a label expansion, not a newly successful trial. [1,2]

For Novartis investors, the opportunity is to turn an existing anti-IL-17A product into a useful treatment in another defined population. That can make use of established product capabilities, but an additional indication is not automatically an additional revenue stream of a calculable size.

The comparison includes the taper

REPLENISH randomized 381 patients across three groups, including two secukinumab doses and placebo, with a common 24-week prednisone taper. In the November US label, the 150 mg comparison reports sustained remission in 51/126 patients versus 26/127 on placebo, or 40.5% versus 20.5%. The model-based difference is 20.2 percentage points, with a 95% confidence interval of 9.4 to 31.0; the reported multiplicity-adjusted p value is below 0.01. Remission had to begin by week 12 and persist through week 52 without a qualifying flare or new giant-cell arteritis requiring rescue. [2]

That endpoint connects disease control with an attempt to reduce steroids. It does not show that every patient can stop steroids, or that an individual should follow the research taper without clinical supervision. The shared taper makes the randomized comparison interpretable; it is part of the treatment strategy being tested.

The journal abstract reports 40.6% versus 20.4%, with 127 randomized to each arm. The label explains that one patient in each secukinumab group was randomized but not treated, and gives the treated denominators above. These percentages should be attributed to their respective sources rather than mixed. The complete paper, protocol and statistical analysis plan were not obtained; the peer-reviewed abstract and the relevant full prescribing-information sections were reviewed. [2,3]

Meaningful control is not the same as proven avoidance of every steroid complication

The abstract reports adjusted annual cumulative glucocorticoid exposure of 1683.2 mg in the 150 mg group versus 2093.0 mg with placebo. This supports a steroid-sparing effect under the study conditions. It is not direct proof of fewer fractures, cardiovascular events or hospitalizations. A commercial argument based on avoided complications needs evidence for those outcomes and associated costs, rather than assuming every reduction in dose produces a fixed financial saving. [3]

The US regimen is 150 mg subcutaneously at weeks 0, 1, 2, 3 and 4, then every four weeks with a tapering glucocorticoid course; it may continue alone after steroid discontinuation. That defines a delivery pathway with early loading and later maintenance. It does not establish how long patients will remain on treatment in practice. [2]

Safety affects that pathway. The publication reports serious adverse events in 15.9% of the 150 mg group and 14.2% of placebo recipients; the label identifies a fatal cryptococcal meningitis case in a Cosentyx-treated PMR patient. Urinary tract infection and hypersensitivity were more frequent in the PMR label comparison. Screening, infection management and patient selection remain relevant. Similar-looking overall serious-event percentages do not prove equivalent safety, and experience in other indications does not remove PMR-specific concerns. [1–3]

Position it against the actual choices

Secukinumab inhibits IL-17A. Sarilumab, marketed as Kevzara, targets the IL-6 receptor and already has a US PMR indication for adults with inadequate steroid response or inability to tolerate tapering. Its label specifies 200 mg subcutaneously every two weeks with a steroid taper and permits monotherapy afterward. These are different mechanisms within the same disease pathway, not two versions of the same target. [4]

Cosentyx therefore expands choice; it does not create the first biologic-treated PMR market. Neither trial establishes superiority over the other medicine. Differences in populations, endpoints and taper schedules make an informal cross-trial ranking unreliable. Less frequent maintenance administration may matter to some patients, but net price, clinical fit, monitoring and payer policy also influence selection.

Build an incremental market, not a prevalence multiplication

An investment model should start with patients who meet the label, reach specialist assessment and are suitable for the treatment. It should then distinguish covered access, actual starts and time receiving therapy. People successfully managed with existing treatment are not automatic new Cosentyx users; nor is every switch from a competitor a newly treated patient.

A practical revenue model can use treated patient-years multiplied by realized net revenue per patient-year, while separately accounting for loading, discontinuations and rebates. The relevant profit contribution then depends on manufacturing, distribution, medical support and incremental commercial spending. This note assigns no unverified price, uptake rate, sales estimate or target valuation.

There is also a distinction between franchise efficiency and economic certainty. An established biologic may share infrastructure across indications, but the extent of savings has not been quantified here. Adding assumed PMR sales to an existing total-product forecast can double count growth if that forecast already includes the expansion. The analyst needs to reconcile the base case before treating the approval as wholly incremental.

The next validation is clinical and commercial

Longer follow-up can test durability beyond the randomized year, treatment discontinuation and cumulative harms. Comparative evidence could help define when an IL-17A approach is preferable to another strategy. Real-world prescribing and reimbursement data can test whether eligible patients actually start and remain on treatment. These are separate questions, and none can be answered by the approval headline alone.

Cosentyx brings a supported option to patients for whom steroid management remains difficult. Its investment contribution will depend on converting that evidence into sustained, appropriately selected use at an economic cost that patients, payers and Novartis can support.

Sources and scope

[1] Novartis US release, November 16, 2026; global release November 17. Approval announcement, evidence dates and attributed company interpretation. https://www.novartis.com/us-en/news/media-releases/novartis-cosentyx-becomes-first-and-only-fda-approved-anti-il-17-biologic-people-polymyalgia-rheumatica-pmr https://www.novartis.com/news/media-releases/novartis-cosentyx-becomes-first-and-only-fda-approved-anti-il-17-biologic-people-polymyalgia-rheumatica-pmr

[2] Cosentyx US prescribing information, November 2026 updates. Sections 1.7, 2.12, 5, 6.1 and 14.8 reviewed for eligibility, regimen, safety and label-specific analysis. Manufacturer-hosted official label; complete FDA review package not obtained. https://www.novartis.com/us-en/sites/novartis_us/files/cosentyx.pdf

[3] Stone et al. Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica. NEJM, online June 3, 2026; print August 13. DOI 10.1056/NEJMoa2602567; PMID 42234540. Peer-reviewed abstract reviewed; full article, supplement and SAP not obtained. Registry identifier NCT05767034. https://pubmed.ncbi.nlm.nih.gov/42234540/ https://www.nejm.org/doi/full/10.1056/NEJMoa2602567 https://clinicaltrials.gov/study/NCT05767034

[4] Kevzara US prescribing information, retrieved November 17, 2026. PMR indication and dosing reviewed for treatment positioning, not cross-trial superiority. https://products.sanofi.us/kevzara/kevzara.pdf

BioScore

3.7/10
Cautious